Selling pharmaceuticals and other health care products in China is increasingly fraught with peril. China is accusing GlaxoSmithKline of funnelling payments through travel agents to doctors, hospitals and government officials to bolster drug sales.
Selling pharmaceuticals and other health care products in China is increasingly fraught with peril. China is accusing GlaxoSmithKline of funnelling payments through travel agents to doctors, hospitals and government officials to bolster drug sales.